Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP Jr, Mian BM. Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. J Urol 2005; 173: 70–72.
Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 2014; 120: 190–196.
Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ. Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: results from the REDUCE study. Prostate 2015; 75: 1492–1498.
Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ. Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study. Prostate Cancer Prostatic Dis 2016; 19: 180–184.
Moreira DM, Bostwick DG, Andriole GL, Peterson BL, Cohen HJ, Castro-Santamaria R et al. Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy. J Urol 2015; 194: 1241–1246.
Servian P, Celma A, Planas J, Placer J, de Torres IM, Olivan M et al. Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies. Prostate 2015; 75: 1669–1675.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192–1202.
Abrahams NA, Bostwick DG, Ormsby AH, Qian J, Brainard JA. Distinguishing atrophy and high-grade prostatic intraepithelial neoplasia from prostatic adenocarcinoma with and without previous adjuvant hormone therapy with the aid of cytokeratin 5/6. Am J Clin Pathol 2003; 120: 368–376.
Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178: 896–900.
Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 2011; 14: 326–331.
Berney DM, Algaba F, Camparo P, Comperat E, Griffiths D, Kristiansen G et al. Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch 2014; 464: 583–587.
Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000; 37: 404–412.
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 2014; 66: 619–622.
Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G et al. Evaluation of prostatitis in autopsied prostates—is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736–1740.
Postma R, Schroder FH, van der Kwast TH. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology 2005; 65: 745–749.
Porcaro AB, Novella G, Molinari A, Terrin A, Minja A, De Marco V et al. Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer. Urol Int 2015; 94: 270–285.
Yun BH, Hwang EC, Yu HS, Chung H, Kim SO, Jung SI et al. Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy? Int Urol Nephrol 2015; 47: 1251–1257.
Brasil AA, Favaro WJ, Cagnon VH, Ferreira U, Billis A. Atrophy in specimens of radical prostatectomy: is there topographic relation to high-grade prostatic intraepithelial neoplasia or cancer? Int Urol Nephrol 2011; 43: 397–403.
Billis A, Magna LA. Inflammatory atrophy of the prostate. Prevalence and significance. Arch Pathol Lab Med 2003; 127: 840–844.
Iczkowski KA, Torkko KC, Wilson RS, Lucia MS, Bostwick DG. Prostatic atrophy: its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides. Hum Pathol 2014; 45: 54–58.
De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006; 30: 1281–1291.
Wang W, Bergh A, Damber JE. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate 2009; 69: 1378–1386.
Van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003; 162: 1529–1537.
Celma A, Servián P, Planas J, Placer J, Quilez MT, Arbós MA et al. Clinical significance of proliferative inflammatory atrophy in prostate biopsy. Acta Urol Esp 2014; 38: 122–126.
Servian P, Celma A, Planas J, Placer J, de Torres IM, Morote J. Clinical significance of proliferative inflammatory atrophy in negative prostatic biopsies. Prostate 2016; 76: 1501–1506.
Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 2007; 69: 103–107.
Freitas DM, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM. Extent of baseline prostate atrophy is associated with lower incidence of low- and high-grade prostate cancer on repeat biopsy. Urology 2016; 103: 161–166.